Search company, investor...
Follica company logo

Follica

follicabio.com

Founded Year

2005

Stage

Unattributed VC | Alive

Total Raised

$24M

Last Raised

$7.5M | 12 yrs ago

About Follica

Follica develops novel therapies for conditions and disorders of the hair follicle, the epicenter for the development and replenishment of human hair and skin.

Headquarters Location

88 East Main Street Suite H-501

Mendham, New Jersey, 07945,

United States

973-543-2225

Missing: Follica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Follica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Follica Patents

Follica has filed 1 patent.

The 3 most popular patent topics include:

  • Hair diseases
  • Human hair
  • Hair loss medications
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2018

12/28/2021

Human hair, Androgens and anabolic steroids, Androstanes, Hair diseases, Transcription factors

Grant

Application Date

10/18/2018

Grant Date

12/28/2021

Title

Related Topics

Human hair, Androgens and anabolic steroids, Androstanes, Hair diseases, Transcription factors

Status

Grant

Latest Follica News

PureTech confirms negotiations for a possible Nektar merger

Oct 9, 2022

October 9, 2022 Rumours that Nektar Therapeutics may be talking about a merger with healthcare holding company PureTech have been confirmed by the two companies. UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal. The possible merger has been announced a few months after Nektar was forced into a major restructuring programme following the failure of its Bristol-Myers Squibb-partnered  immuno- oncology candidate bempegaldesleukin which was discontinued in April after it failed late-stage trials . Nektar shed 70% of its workforce as a result and refocused its R&D on NKTR-358, an IL-2 conjugate regulatory T cell stimulator for inflammatory conditions like lupus and atopic dermatitis partnered with Eli Lilly, and IL-15 agonist candidate NKTR-255 for cancer. Both are in early- to mid-stage clinical testing. The company said at the time the reduction in headcount would eke out its cash reserves – forecast to be around $450 million at the end of this year – and allow it to continue operating into 2025. According to PureTech, the negotiations cover a combination of the businesses “which may include, amongst other things, an offer for share capital.” Under UK regulations, Nektar will have to come up with a firm offer by end of working day 3 November or indicate that it will not be moving ahead with a deal – although that deadline can be extended with prior agreement. While the merger would create a combined company with significant cash reserves – PureTech ended last year with around $466 million in liquid reserves that it also said would fund operations into 2025 – investors seem uncertain about the merits or indeed the rationale of the deal. The possibility of a transaction has weighed heavily on PureTech shares, dragging them down more than 20% after it issued the statement acknowledging the negotiations. One link between the two companies lies in PureTech’s president and chief business officer Bharat Chowiria, note analysts at Mizuho. Chowiria was previously chairman and CBO at Nektar 2011 when it was trying to build a business in respiratory therapeutics including a now-defunct inhaled formulation of insulin. The analysts point that merging the businesses will diversify risk and give greater scale, but could also lead to more “complexity” in operations. Nektar’s pipeline would add to various in-house projects at PureTech currently headed by LYT-100 (deupirfenidone), a tweaked version of established therapy for idiopathic pulmonary fibrosis which has reached the phase 2 testing stage. PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Don't miss your daily pharmaphorum news.

Follica Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Follica Rank

Follica Frequently Asked Questions (FAQ)

  • When was Follica founded?

    Follica was founded in 2005.

  • Where is Follica's headquarters?

    Follica's headquarters is located at 88 East Main Street, Mendham.

  • What is Follica's latest funding round?

    Follica's latest funding round is Unattributed VC.

  • How much did Follica raise?

    Follica raised a total of $24M.

  • Who are the investors of Follica?

    Investors of Follica include InterWest Partners, Polaris Partners and Science Center.

  • Who are Follica's competitors?

    Competitors of Follica include Artas, ISTO Technologies, Cellular Engineering Technologies, CyDen, InCytu and 12 more.

Compare Follica to Competitors

MDSolarSciences Logo
MDSolarSciences

MDSolarSciences develops sun protection, skin care and skin cancer prevention products. The company is committed to providing the safest sunscreens for sensitive skin, rosacea, acne, eczema and psoriasis.

Thermage Logo
Thermage

Thermage markets non-invasive skin tightening devices for cosmetic indications. The system heats the deep skin tissues, causing collagen shrinkage, while cooling the skin surface.  No incisions are required and side effects associated with lasers are avoided. The technology has multiple potential applications, including treatments for facial skin tightening, acne and acne scarring, stretch marks, breast lifting and fat dissipation. Several types of disposable treatment tips are designed for various applications and anatomic sites. Thermage has secured regulatory clearance for marketing the system.

A
Advanced Skin Technology

Advanced Skin Technology is the developer of Green Cream, a high potency retinol formulated to repair sun damage and reverse the effects of aging skin. Green Cream's delivery mechanism, Green Polymer Cooling Gel (GPCG) aims to allow it to carry one of the highest concentrations of retinol on the market today.

A
Applisonix

Applisonix is Applisonix was founded in 2004 with a goal of developing aesthetic solutions that are safe, effective, and suitable for everyone.

N
Niadyne

Niadyne Inc is developing a unique approach to skin care that involves enhancing the cellular mechanisms which repair skin cell DNA damage through compounds incorporated into topical creams. go to top

P
Pericor

Pericor offers skin adhesion technology

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.